Cellyan Biotechnology received an additional 180-day extension from Nasdaq to meet the minimum $1.00 bid price requirement, pushing the compliance deadline to January 11, 2027. This news led to a significant after-hours stock drop, reflecting investor concern about the company's ability to avoid delisting despite the extended period.
Cellyan Biotechnology (HKPD) announced it received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price rule. This is a critical development as failure to comply could lead to delisting from the Nasdaq Capital Market. While the extension provides more time, the market reacted negatively, with shares sinking over 20% after hours, indicating investor skepticism about the company's ability to meet the requirement. The company mentioned a reverse stock split as a potential measure, which often dilutes existing shareholders and can be viewed negatively. This situation poses a significant short-term risk for HKPD shareholders due to ongoing uncertainty and potential delisting, with long-term implications for its market access and capital-raising capabilities.